What is the success rate of Cabometyx (cabozantinib)?
Official answer
by Drugs.comCabometyx (cabozantinib) is a tyrosine kinase inhibitor used to treat certain patients with advanced renal cell carcinoma, hepatocellular (liver) cancer, or advanced or metastatic differentiated thyroid cancer.
It is a chemotherapy drug that you take until your cancer starts to get worse - disease progression - or you can no longer tolerate the drug because of side effects or adverse reactions.
How successful Cabometyx is can be measured by how long patients take the treatment for, how long they survive for without their cancer getting worse (progression-free survival), how many months they remain alive for while taking the treatment and how many patients respond to the drug.
How effective is Cabometyx?
| Trial | Duration of treatment | Median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) |
| METEOR - advanced renal cell carcinoma |
Cabometyx: 7.6 months (range 0.3 - 20.5) vs Everolimus (Afinitor): 4.4 months (range 0.21 - 18.9) |
PFS Cabometyx: 7.4 months (95% CI 5.6, 9.1) vs Everolimus: 3.8 months (95% CI 3.7, 5.4) OS Partial responses only Cabometyx: 17% (95% CI 13%, 22%) vs Everolimus: 3% (95% CI 2%, 6%) |
| CABOSUN - advance renal cell carcinoma |
Cabometyx: 6.5 months (range 0.2 - 28.7) vs Sunitinib (Sutent): 3.1 months (range 0.2 - 25.5) |
PFS Cabometyx: 8.6 months (95% CI 6.8, 14.0) vs Everolimus: 5.3 months (95% CI 3.0, 8.2) ORR |
| CHECKMATE-9ER - advanced renal cell carcinoma, first-line treatment | Cabometyx plus nivolumab (Opdivo): 14 months (range 0.2 - 27) |
PFS Cabometyx: 16.6 months (95% CI 12.5, 24.9) vs Sunitinib: 8.3 months (95% CI 7.0, 9.7) OS Complete and partial responses Cabometyx: 55.7% (95% CI 50.1, 61.2) vs Sunitinib: 27.1% (95% CI 22.4, 32.3) |
| CELESTIAL - advanced hepatocellular carcinoma |
Cabometyx: 3.8 months (range 0.1 - 37.3) vs Placeo: 2.0 months (range 0.0 - 27.2) |
PFS Cabometyx: 5.2 months (95% CI 4.0, 5.5) vs Placebo: 1.9 months (95% CI 1.9, 1.9) OS Partial responses only Cabometyx: 4% (95% CI2.3, 6.0) vs Placebo: 0.4% (95% CI 0.0, 2.3) |
| COSMIC-311 - radioiodine-refractory differentiated thyroid cancer previously treated with VEGFR-targeted therapy |
PFS (updated analysis) Cabometyx: 11 months (95% CI 7.4, 13.8) vs Placebo: 1.9 months (95% CI 1.9, 3.7) ORR (updated analysis) |
References
- Food and Drug Administration (FDA). Cabometyx. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf. [Accessed September 27, 2021].
Related medical questions
- Is Cabometyx a chemotherapy drug?
- How does Cabometyx work?
- How long do you take Cabometyx for?
- Does Cabometyx (cabozantinib) cure cancer?
- What is the difference between Cabometyx and Cometriq?
Drug information
Related support groups
- Cabometyx (6 questions, 9 members)
- Cabozantinib (4 questions, 5 members)
- Renal Cell Carcinoma (20 questions, 98 members)
- Hepatocellular Carcinoma (10 questions, 22 members)
- Thyroid Cancer (5 questions, 43 members)